<DOC>
	<DOCNO>NCT00870220</DOCNO>
	<brief_summary>This multicenter , randomize , control , semi-blinded study compare two low dos estradiol administer recently available transdermal patch initiation puberty Turner syndrome girl 11.5-13.0 year old conjunction growth hormone ( GH ) therapy . The specific hypothesis test : combined growth hormone ( GH ) treatment , low dose transdermal estradiol ( LTE2 ) replacement effective stimulating feminization , height velocity , bone mineral density without compromise growth potential low dose transdermal estradiol ( VLTE2 ) , turn superior GH alone effect feminization , height velocity , bone mineral density .</brief_summary>
	<brief_title>Initiating Transdermal Estradiol Therapy Turner 's Syndrome</brief_title>
	<detailed_description>Determining estrogen replacement regimen optimal GH therapy important issue management Turner syndrome today . The estrogen effect growth biphasic , stimulatory low dose inhibitory high dos ( 1 ) . In addition , form , route , time estrogen seem important determinant estrogen effect growth ( 2 ) . Pubertal estrogen replacement treatment customarily delay 15 year age USA give GH treatment time act standard estrogen treatment inhibits growth ( 3 ) , part direct effect epiphyseal senescence fusion ( 4 , 5 ) part act GH antagonist ( 6 ) . Our pilot study suggest form route estrogen important determinant estrogen effect growth ( 2 , 7 ) . We recently find low dos parenteral ( IM depot ) estradiol ( E2 ) together recombinant growth hormone ( GH ) Turner syndrome patient young 12-12.9 year age produce significantly great adult height standard dos oral conjugate estrogen age ( 7 ) . Thus , low dos natural estrogen ( estradiol , E2 ) administer systemic circulation seem optimal growth stimulation . Very little data available optimal E2 dose stimulation epiphyseal growth may relate optimal dosage accrual bone mineral density feminization . Our recent pilot study start depot E2 dose 0.2 mg ; monthly dose increase 0.2 mg successive 6-month interval . The low dose ( 0.2 mg ) stimulate height velocity . However , stimulate breast development reliably large dos ( ≥ 0.4 mg monthly ) , also growth stimulatory although less extent . We propose resolve question whether disparity due invariable sequential administration successively large dos inaccuracy delivery low dos injection , also compare effect bone mineral density equivalent low low dos E2 deliver transdermal patch . Transdermal E2 delivery system available easily reliably deliver comparable low dos E2 form suitable routine patient care . The current guideline recommend start E2 start dose induction puberty ( 5-12.5 mcg daily ) one-tenth one-eighth adult dose ( 100 mcg daily ) ( 8 ) . However , guideline note establish whether various mean patch dose fractionation ( e.g. , administering quarter patch overnight daily administer whole patch 7-10 day per month ) equivalent . Pharmacokinetic study transdermal E2 Turner syndrome teen show absorption E2 first order kinetics ( 9 ) . Steady state achieve approximately 9 hrs application 37.5 µg patch , serum concentration reach mean 52.9 ± 17.8 ( SD ) pg/ml . This demonstrate rise plasma estradiol 1 pg/ml ( 3.67 pmol/l ) every 1.0 µg apply skin , similar package insert data adult . This would suggest start dose 5-10 ug transdermal E2 daily approximate 133-266 µg monthly amount E2 deliver 0.2-0.4 mg monthly injection E2 cypionate . Our preliminary data support extrapolation . In n = 3 Turner syndrome patient combine transdermal E2 dose 17.8 ± 2.1 ( SD ) mcg average 14 day month GH therapy 1.0 year show increase breast tissue diameter 1.8 ± 0.3 cm ( i.e. , breast budding ) , bone mineral density 0.067 ± 0.06 gm/cm2 lumbar spine , height velocity 5.16 ± 1.37 cm/year . The new VLTE2 ( 14 mcg ) patch increase lumbar spine bone mineral density 2.4 % 1 year post-menopausal woman ( P &lt; 0.001 ) , trial conduct child ( package insert ) . We propose move beyond proof principle systemic administration low low dose E2 efficacious practical application E2 treatment . Our study use IM depot E2 ( E2 cyclopentylpropionate , two-thirds E2 ) , low dos require compound pharmacy prepare stock solution 1.0 mg/cc . This helpful compliance , necessarily accurate certainly convenient routine dispensing prescription . Practically , propose extrapolate experience parenteral readily available highly acceptable transdermal preparation : 14 mcg patch worn 10 day month delivers E2 profile approximately equivalent 0.2 mg monthly dose depot E2 , 25 mcg patch wear 10 day month approximately equivalent 0.4 mg monthly dose depot E2 ( 7 ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>60 subject recruit participate Pediatric Endocrinology Clinics United States . Subjects 11.513.0 year age must complete least 6 month GH therapy prior study . Subjects may estrogen prior study . All subject must breast stage 1 euthyroid prior study Those thyroid medication continue appropriate thyroid replacement therapy study . On estrogen therapy , breast stage 2 great , GH least 6 month .</criteria>
	<gender>Female</gender>
	<minimum_age>138 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Turner 's Syndrome</keyword>
</DOC>